Cargando…
Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
Dopamine dysregulation syndrome (DDS) consists of a series of complications such as compulsive use of dopaminergic medications, aggressive or hypomanic behaviors during excessive use, and withdrawal states characterized by dysphoria and anxiety, caused by long-term dopaminergic treatment in patients...
Autores principales: | Mizushima, Jin, Takahata, Keisuke, Kawashima, Noriko, Kato, Motoichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465018/ https://www.ncbi.nlm.nih.gov/pubmed/22769562 http://dx.doi.org/10.1186/1744-859X-11-19 |
Ejemplares similares
-
Effects of Dopamine D(2) Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-(11)C]DOPA
por: Ito, Hiroshi, et al.
Publicado: (2012) -
Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
por: Costa, M.L., et al.
Publicado: (2022) -
High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
por: Reynolds, Gavin P
Publicado: (2021) -
The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
por: Delcourte, Sarah, et al.
Publicado: (2018) -
Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
por: Seeman, P
Publicado: (2016)